1、 LISS A,OOI C H,ZJABLOVSKAJA P,et al.The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors[J].Haematologica,2014,99(4):697-705. LISS A,OOI C H,ZJABLOVSKAJA P,et al.The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors[J].Haematologica,2014,99(4):697-705.
2、 ADAMO A,CHIN P,KEANE P,et al.Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia[J].Leukemia,2023,37(1):102-112. ADAMO A,CHIN P,KEANE P,et al.Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia[J].Leukemia,2023,37(1):102-112.
3、 VERGEZ F,LARGEAUD L,BERTOLI S,et al.Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups,and outcome in acute myeloid leukemia[J].Blood Cancer J,2022,12(8):117. VERGEZ F,LARGEAUD L,BERTOLI S,et al.Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups,and outcome in acute myeloid leukemia[J].Blood Cancer J,2022,12(8):117.
4、 SNADDON J,SMITH M L,NEAT M,et al.Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2[J].Genes Chromosomes Cancer,2003,37(1):72-78. SNADDON J,SMITH M L,NEAT M,et al.Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2[J].Genes Chromosomes Cancer,2003,37(1):72-78.
5、 NGUYEN C H,GRANDITS A M,PURTON L E,et al.All-trans retinoic acid in non-promyelocytic acute myeloid leukemia:driver lesion dependent effects on leukemic stem cells[J].Cell Cycle,2020,19(20):2573-2588. NGUYEN C H,GRANDITS A M,PURTON L E,et al.All-trans retinoic acid in non-promyelocytic acute myeloid leukemia:driver lesion dependent effects on leukemic stem cells[J].Cell Cycle,2020,19(20):2573-2588.
6、 NI X,HU G,CAI X.The success and the challenge of all-trans retinoic acid in the treatment of cancer[J].Crit Rev Food Sci Nutr,2019,59(sup1):S71-S80. NI X,HU G,CAI X.The success and the challenge of all-trans retinoic acid in the treatment of cancer[J].Crit Rev Food Sci Nutr,2019,59(sup1):S71-S80.
7、 LO-COCO F,AVVISATI G,VIGNETTI M,et al.Retinoic acid and arsenic trioxide for acute promyelocytic leukemia[J].N Engl J Med,2013,369(2):111-121. LO-COCO F,AVVISATI G,VIGNETTI M,et al.Retinoic acid and arsenic trioxide for acute promyelocytic leukemia[J].N Engl J Med,2013,369(2):111-121.
8、 BRAUN T P,COBLENTZ C,DANIEL J COLEMAN B M,et al.Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia[J].Proc Natl Acad Sci U S A,2020,117(24):13670-13679. BRAUN T P,COBLENTZ C,DANIEL J COLEMAN B M,et al.Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia[J].Proc Natl Acad Sci U S A,2020,117(24):13670-13679.
9、 LAVALí V-P,KROSL J,LEMIEUX S,et al.Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors[J].Blood,2016,127(24):3054-3061. LAVALí V-P,KROSL J,LEMIEUX S,et al.Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors[J].Blood,2016,127(24):3054-3061.
10、 SCHMIDT L,HEYES E,SCHEIBLECKER L,et al.CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex[J].Leukemia,2019,33(7):1608-1619. SCHMIDT L,HEYES E,SCHEIBLECKER L,et al.CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex[J].Leukemia,2019,33(7):1608-1619.
11、 ZHANG H,ALBERICH-JORDA M,AMABILE G,et al.Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia[J].Cancer Cell,2013,24(5):575-588. ZHANG H,ALBERICH-JORDA M,AMABILE G,et al.Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia[J].Cancer Cell,2013,24(5):575-588.
12、 ARSLAN S,ZHANG J,DHAKAL P,et al.Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia[J].Am J Hematol,2021,96(3):E59-E63. ARSLAN S,ZHANG J,DHAKAL P,et al.Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia[J].Am J Hematol,2021,96(3):E59-E63.
13、 D?HNER H,WEI A H,APPELBAUM F R,et al.Diagnosis and management of AML in adults:2022 recommendations from an international expert panel on behalf of the ELN[J].Blood,2022,140(12):1345-1377. D?HNER H,WEI A H,APPELBAUM F R,et al.Diagnosis and management of AML in adults:2022 recommendations from an international expert panel on behalf of the ELN[J].Blood,2022,140(12):1345-1377.
14、 WANG J,JIANG H,JING Y,et al.Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA[J].Br J Haematol,2022,198(1):e3-e8. WANG J,JIANG H,JING Y,et al.Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA[J].Br J Haematol,2022,198(1):e3-e8.
15、 WANG J,LU R Q,WU Y,et al.Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA[J].Br J Haematol,2020,190(4):533-544. WANG J,LU R Q,WU Y,et al.Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA[J].Br J Haematol,2020,190(4):533-544.
16、 TIEN F M,YAO C Y,TSAI X C H,et al.Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations[J].Blood Cancer J,2024,14(1):15. TIEN F M,YAO C Y,TSAI X C H,et al.Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations[J].Blood Cancer J,2024,14(1):15.
17、 SU L,GAO S J,TAN Y H,et al.CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations[J].Ann Hematol,2019,98(7):1641-1646. SU L,GAO S J,TAN Y H,et al.CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations[J].Ann Hematol,2019,98(7):1641-1646.
18、 AHN J S,KIM J Y,KIM H J,et al.Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant[J].Ann Hematol,2016,95(2):301-310. AHN J S,KIM J Y,KIM H J,et al.Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant[J].Ann Hematol,2016,95(2):301-310.
19、 KUROSAWA S,YAMAGUCHI H,YAMAGUCHI T,et al.The prognostic impact of FLT3-ITD,NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse[J].Int J Hematol,2020,112(2):200-209. KUROSAWA S,YAMAGUCHI H,YAMAGUCHI T,et al.The prognostic impact of FLT3-ITD,NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse[J].Int J Hematol,2020,112(2):200-209.
20、 FORSBERG M,KONOPLEVA M.AML treatment:conventional chemotherapy and emerging novel agents[J].Trends Pharmacol Sci,2024,45(5):430-448. FORSBERG M,KONOPLEVA M.AML treatment:conventional chemotherapy and emerging novel agents[J].Trends Pharmacol Sci,2024,45(5):430-448.
21、 ROWE J M.The “7+3” regimen in acute myeloid leukemia[J].Haematologica,2022,107(1):3. ROWE J M.The “7+3” regimen in acute myeloid leukemia[J].Haematologica,2022,107(1):3.
22、 WANG D,SUN T,XIA Y,et al.Homodimer-mediated phosphorylation of C/EBPα-p42 S16 modulates acute myeloid leukaemia differentiation through liquid-liquid phase separation[J].Nat Commun,2023,14(1):6907. WANG D,SUN T,XIA Y,et al.Homodimer-mediated phosphorylation of C/EBPα-p42 S16 modulates acute myeloid leukaemia differentiation through liquid-liquid phase separation[J].Nat Commun,2023,14(1):6907.
23、 CHEN X,ZHOU W,SONG R H,et al.Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity[J].Sci Adv,2022,8(4):eabl5220. CHEN X,ZHOU W,SONG R H,et al.Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity[J].Sci Adv,2022,8(4):eabl5220.
24、 BARARIA D,KWOK H S,WELNER R S,et al.Acetylation of C/EBPα inhibits its granulopoietic function[J].Nat Commun,2016(7):10968. BARARIA D,KWOK H S,WELNER R S,et al.Acetylation of C/EBPα inhibits its granulopoietic function[J].Nat Commun,2016(7):10968.
25、 GENTLE I E,MOELTER I,BADR M T,et al.The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression[J].Cell Death Dis,2021,12(7):675. GENTLE I E,MOELTER I,BADR M T,et al.The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression[J].Cell Death Dis,2021,12(7):675.
26、 BERESHCHENKO O,MANCINI E,MOORE S,et al.Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPα mutant AML[J].Cancer Cell,2009,16(5):390-400. BERESHCHENKO O,MANCINI E,MOORE S,et al.Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPα mutant AML[J].Cancer Cell,2009,16(5):390-400.
27、 TOGAMI K,KITAURA J,UCHIDA T,et al.A C-terminal mutant of CCAAT-enhancer-binding protein α(C/EBPα-Cm)downregulates Csf1r,a potent accelerator in the progression of acute myeloid leukemia with C/EBPα-Cm[J].Exp Hematol,2015,43(4):300-308. TOGAMI K,KITAURA J,UCHIDA T,et al.A C-terminal mutant of CCAAT-enhancer-binding protein α(C/EBPα-Cm)downregulates Csf1r,a potent accelerator in the progression of acute myeloid leukemia with C/EBPα-Cm[J].Exp Hematol,2015,43(4):300-308.
28、 GOMBART A F,HOFMANN W K,KAWANO S,et al.Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias[J].Blood,2002,99(4):1332-1340. GOMBART A F,HOFMANN W K,KAWANO S,et al.Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias[J].Blood,2002,99(4):1332-1340.
29、 PORSE B T,BRYDER D,THEILGAARD-M?NCH K,et al.Loss of C/EBPα cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage[J].J Exp Med,2005,202(1):85-96. PORSE B T,BRYDER D,THEILGAARD-M?NCH K,et al.Loss of C/EBPα cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage[J].J Exp Med,2005,202(1):85-96.
30、 PORSE B T,PEDERSEN T ?,XU X,et al.E2F repression by C/EBPα is required for adipogenesis and granulopoiesis in vivo[J].Cell,2001,107(2):247-258. PORSE B T,PEDERSEN T ?,XU X,et al.E2F repression by C/EBPα is required for adipogenesis and granulopoiesis in vivo[J].Cell,2001,107(2):247-258.
31、 HEYES E,SCHMIDT L,MANHART G,et al.Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML[J].Leukemia,2021,35(9):2526-2538. HEYES E,SCHMIDT L,MANHART G,et al.Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML[J].Leukemia,2021,35(9):2526-2538.
32、 JAKOBSEN J S,LAURSEN L G,SCHUSTER M B,et al.Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML[J].Sci Adv,2019,5(7):eaaw4304. JAKOBSEN J S,LAURSEN L G,SCHUSTER M B,et al.Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML[J].Sci Adv,2019,5(7):eaaw4304.
33、 GELETU M,BALKHI M Y,PEER ZADA A A,et al.Target proteins of C/EBPalphap30 in AML:C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9[J].Blood,2007,110(9):3301-3309. GELETU M,BALKHI M Y,PEER ZADA A A,et al.Target proteins of C/EBPalphap30 in AML:C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9[J].Blood,2007,110(9):3301-3309.
34、 RAMBERGER E,SAPOZHNIKOVA V,KOWENZ-LEUTZ E,et al.PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα[J].iScience,2021,24(6):102686. RAMBERGER E,SAPOZHNIKOVA V,KOWENZ-LEUTZ E,et al.PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα[J].iScience,2021,24(6):102686.
35、 YE M,ZHANG H,YANG H,et al.Hematopoietic differentiation is required for initiation of acute myeloid leukemia[J].Cell Stem Cell,2015,17(5):611-623. YE M,ZHANG H,YANG H,et al.Hematopoietic differentiation is required for initiation of acute myeloid leukemia[J].Cell Stem Cell,2015,17(5):611-623.
36、 GEORGI J A,STASIK S,KRAMER M,et al.Prognostic impact of CEBPA mutational subgroups in adult AML[J].Leukemia,2024,38(2):281-290. GEORGI J A,STASIK S,KRAMER M,et al.Prognostic impact of CEBPA mutational subgroups in adult AML[J].Leukemia,2024,38(2):281-290.
37、 ZHANG F,SHEN Z,XIE J,et al.CEBPA bZIP in-frame mutations in acute myeloid leukemia:prognostic and therapeutic implications[J].Blood Cancer J,2024,14(1):59. ZHANG F,SHEN Z,XIE J,et al.CEBPA bZIP in-frame mutations in acute myeloid leukemia:prognostic and therapeutic implications[J].Blood Cancer J,2024,14(1):59.
38、 AHN S Y,KIM T H,KIM M,et al.Clinical significance of bZIP in-frame CEBPA-mutated normal karyotype acute myeloid leukemia[J].Cancer Res Treat,2023,55(3):1011-1022. AHN S Y,KIM T H,KIM M,et al.Clinical significance of bZIP in-frame CEBPA-mutated normal karyotype acute myeloid leukemia[J].Cancer Res Treat,2023,55(3):1011-1022.
39、 TARLOCK K,LAMBLE A,WANG J,et al.CEBPA bZIP mutations are associated with favorable prognosis in de novo AML:a report from the children's oncology group[J].Blood,2021,138(13):1137-1147. TARLOCK K,LAMBLE A,WANG J,et al.CEBPA bZIP mutations are associated with favorable prognosis in de novo AML:a report from the children's oncology group[J].Blood,2021,138(13):1137-1147.
40、 PABST T,MUELLER B U,ZHANG P,et al.Dominant-negative mutations of CEBPA,encoding CCAAT/enhancer binding protein-α(C/EBPα),in acute myeloid leukemia[J].Nat Genet,2001,27(3):263-270. PABST T,MUELLER B U,ZHANG P,et al.Dominant-negative mutations of CEBPA,encoding CCAAT/enhancer binding protein-α(C/EBPα),in acute myeloid leukemia[J].Nat Genet,2001,27(3):263-270.
41、 SU L,TAN Y H,LIN H,et al.Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance[J].Oncotarget,2018,9(38):24970-24979. SU L,TAN Y H,LIN H,et al.Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance[J].Oncotarget,2018,9(38):24970-24979.
42、 TAUBE F,GEORGI J A,KRAMER M,et al.CEBPA mutations in 4708 patients with acute myeloid leukemia:differential impact of bZIP and TAD mutations on outcome[J].Blood,2022,139(1):87-103. TAUBE F,GEORGI J A,KRAMER M,et al.CEBPA mutations in 4708 patients with acute myeloid leukemia:differential impact of bZIP and TAD mutations on outcome[J].Blood,2022,139(1):87-103.
43、 BULLINGER L.CEBPA mutations in AML:site matters[J].Blood,2022,139(1):6-7. BULLINGER L.CEBPA mutations in AML:site matters[J].Blood,2022,139(1):6-7.
44、 LIN L I,CHEN C Y,LIN D T,et al.Characterization of CEBPA mutations in acute myeloid leukemia:most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells[J].Clin Cancer Res,2005,11(4):1372-1379. LIN L I,CHEN C Y,LIN D T,et al.Characterization of CEBPA mutations in acute myeloid leukemia:most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells[J].Clin Cancer Res,2005,11(4):1372-1379.
45、 CHEN K M,WU J Y,ZHANG Y X,et al.Cebpa is required for haematopoietic stem and progenitor cell generation and maintenance in zebrafish[J].Open Biol,2024,14(11):240215. CHEN K M,WU J Y,ZHANG Y X,et al.Cebpa is required for haematopoietic stem and progenitor cell generation and maintenance in zebrafish[J].Open Biol,2024,14(11):240215.
46、 YUAN H,GAO S,CHEN H,et al.Primitive macrophages are dispensable for HSPC mobilization and definitive hematopoiesis[J].Blood,2019,134(9):782-784. YUAN H,GAO S,CHEN H,et al.Primitive macrophages are dispensable for HSPC mobilization and definitive hematopoiesis[J].Blood,2019,134(9):782-784.
47、 JOHNSON P F.Molecular stop signs:regulation of cell-cycle arrest by C/EBP transcription factors[J].J Cell Sci,2005,118(Pt 12):2545-2555. JOHNSON P F.Molecular stop signs:regulation of cell-cycle arrest by C/EBP transcription factors[J].J Cell Sci,2005,118(Pt 12):2545-2555.
48、 AVELLINO R,DELWEL R.Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation[J].Blood,2017,129(15):2083-2091. AVELLINO R,DELWEL R.Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation[J].Blood,2017,129(15):2083-2091.
49、 OHLSSON E,SCHUSTER M B,HASEMANN M,et al.The multifaceted functions of C/EBPα in normal and malignant haematopoiesis[J].Leukemia,2016,30(4):767-775. OHLSSON E,SCHUSTER M B,HASEMANN M,et al.The multifaceted functions of C/EBPα in normal and malignant haematopoiesis[J].Leukemia,2016,30(4):767-775.
50、 DAI Y M,ZHU L,HUANG Z B,et al.Cebpα is essential for the embryonic myeloid progenitor and neutrophil maintenance in zebrafish[J].J Genet Genomics,2016,43(10):593-600. DAI Y M,ZHU L,HUANG Z B,et al.Cebpα is essential for the embryonic myeloid progenitor and neutrophil maintenance in zebrafish[J].J Genet Genomics,2016,43(10):593-600.
51、 ZHANG P,IWASAKI-ARAI J,IWASAKI H,et al.Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBPα[J].Immunity,2004,21(6):853-863. ZHANG P,IWASAKI-ARAI J,IWASAKI H,et al.Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBPα[J].Immunity,2004,21(6):853-863.
52、 SCHUSTER M B,FRANK A K,BAGGER F O,et al.Lack of the p42 form of C/EBPα leads to spontaneous immortalization and lineage infidelity of committed myeloid progenitors[J].Exp Hematol,2013,41(10):882-893.e16. SCHUSTER M B,FRANK A K,BAGGER F O,et al.Lack of the p42 form of C/EBPα leads to spontaneous immortalization and lineage infidelity of committed myeloid progenitors[J].Exp Hematol,2013,41(10):882-893.e16.
53、 ZHANG D E,ZHANG P,WANG N D,et al.Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice[J].Proc Natl Acad Sci U S A,1997,94(2):569-574. ZHANG D E,ZHANG P,WANG N D,et al.Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice[J].Proc Natl Acad Sci U S A,1997,94(2):569-574.
54、 VINSON C R,HAI T,BOYD S M.Dimerization specificity of the leucine zipper-containing bZIP motif on DNA binding:prediction and rational design[J].Genes Dev,1993,7(6):1047-1058. VINSON C R,HAI T,BOYD S M.Dimerization specificity of the leucine zipper-containing bZIP motif on DNA binding:prediction and rational design[J].Genes Dev,1993,7(6):1047-1058.
55、 GARCIA-CUELLAR M P,AKAN S,SLANY R K.A C/ebpα isoform specific differentiation program in immortalized myelocytes[J].Leukemia,2023,37(9):1850-1859. GARCIA-CUELLAR M P,AKAN S,SLANY R K.A C/ebpα isoform specific differentiation program in immortalized myelocytes[J].Leukemia,2023,37(9):1850-1859.
56、 RAMJI DP,FOKA P.CCAAT/enhancer-binding proteins:structure,function and regulation[J].Biochem J,2002,365(Pt 3):561-575. RAMJI DP,FOKA P.CCAAT/enhancer-binding proteins:structure,function and regulation[J].Biochem J,2002,365(Pt 3):561-575.
57、 MILLER M,SHUMAN J D,SEBASTIAN T,et al.Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein α[J].J Biol Chem,2003,278(17):15178-15184. MILLER M,SHUMAN J D,SEBASTIAN T,et al.Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein α[J].J Biol Chem,2003,278(17):15178-15184.
58、 IN K,ZAINI M A,MüLLER C,et al.Shwachman-Bodian-Diamond syndrome(SBDS)protein deficiency impairs translation re-initiation from C/EBPα and C/EBPβ mRNAs[J].Nucleic Acids Res,2016,44(9):4134-4146. IN K,ZAINI M A,MüLLER C,et al.Shwachman-Bodian-Diamond syndrome(SBDS)protein deficiency impairs translation re-initiation from C/EBPα and C/EBPβ mRNAs[J].Nucleic Acids Res,2016,44(9):4134-4146.
59、 FRIEDMAN A D.C/EBPα in normal and malignant myelopoiesis[J].Int J Hematol,2015,101(4):330-341. FRIEDMAN A D.C/EBPα in normal and malignant myelopoiesis[J].Int J Hematol,2015,101(4):330-341.
60、 HUBER S,BAER C,HUTTER S,et al.AML classification in the year 2023:How to avoid a Babylonian confusion of languages[J].Leukemia,2023,37(7):1413-1420. HUBER S,BAER C,HUTTER S,et al.AML classification in the year 2023:How to avoid a Babylonian confusion of languages[J].Leukemia,2023,37(7):1413-1420.
61、 WAKITA S,SAKAGUCHI M,OH I,et al.Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia[J].Blood Adv,2022,6(1):238-247. WAKITA S,SAKAGUCHI M,OH I,et al.Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia[J].Blood Adv,2022,6(1):238-247.
62、 ARBER D A,ORAZI A,HASSERJIAN R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405. ARBER D A,ORAZI A,HASSERJIAN R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.
63、 WILHELMSON A S,PORSE B T.CCAAT enhancer binding protein alpha(CEBPA)biallelic acute myeloid leukaemia:cooperating lesions,molecular mechanisms and clinical relevance[J].Br J Haematol,2020,190(4):495-507. WILHELMSON A S,PORSE B T.CCAAT enhancer binding protein alpha(CEBPA)biallelic acute myeloid leukaemia:cooperating lesions,molecular mechanisms and clinical relevance[J].Br J Haematol,2020,190(4):495-507.
64、 WOUTERS B J,L?WENBERG B,ERPELINCK-VERSCHUEREN C A J,et al.Double CEBPA mutations,but not single CEBPA mutations,define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome[J].Blood,2009,113(13):3088-3091. WOUTERS B J,L?WENBERG B,ERPELINCK-VERSCHUEREN C A J,et al.Double CEBPA mutations,but not single CEBPA mutations,define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome[J].Blood,2009,113(13):3088-3091.
65、 SCHMIDT L,HEYES E,GREBIEN F.Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia[J].Bioessays,2020,42(2):e1900178. SCHMIDT L,HEYES E,GREBIEN F.Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia[J].Bioessays,2020,42(2):e1900178.
66、 SU L,GAO S J,LIU X L,et al.CEBPA mutations in patients with de novo acute myeloid leukemia:data analysis in a Chinese population[J].Onco Targets Ther,2016(9):3399-3403. SU L,GAO S J,LIU X L,et al.CEBPA mutations in patients with de novo acute myeloid leukemia:data analysis in a Chinese population[J].Onco Targets Ther,2016(9):3399-3403.
67、 NIE Y,SU L,LI W,et al.Novel insights of acute myeloid leukemia with CEBPA deregulation:Heterogeneity dissection and re-stratification[J].Crit Rev Oncol Hematol,2021(163):103379. NIE Y,SU L,LI W,et al.Novel insights of acute myeloid leukemia with CEBPA deregulation:Heterogeneity dissection and re-stratification[J].Crit Rev Oncol Hematol,2021(163):103379.
68、 YANG X,WANG J.Precision therapy for acute myeloid leukemia[J].J Hematol Oncol,2018,11(1):3. YANG X,WANG J.Precision therapy for acute myeloid leukemia[J].J Hematol Oncol,2018,11(1):3.
69、 BHANSALI R S,PRATZ K W,LAI C.Recent advances in targeted therapies in acute myeloid leukemia[J].J Hematol Oncol,2023,16(1):29. BHANSALI R S,PRATZ K W,LAI C.Recent advances in targeted therapies in acute myeloid leukemia[J].J Hematol Oncol,2023,16(1):29.
70、 NEWELL L F,COOK R J.Advances in acute myeloid leukemia[J].BMJ,2021(375):n2026. NEWELL L F,COOK R J.Advances in acute myeloid leukemia[J].BMJ,2021(375):n2026.
71、 SHALLIS R M,WANG R,DAVIDOFF A,et al.Epidemiology of acute myeloid leukemia:Recent progress and enduring challenges[J].Blood Rev,2019(36):70-87. SHALLIS R M,WANG R,DAVIDOFF A,et al.Epidemiology of acute myeloid leukemia:Recent progress and enduring challenges[J].Blood Rev,2019(36):70-87.
72、 SHORT N J,RYTTING M E,CORTES J E.Acute myeloid leukaemia[J].Lancet,2018,392(10147):593-606. SHORT N J,RYTTING M E,CORTES J E.Acute myeloid leukaemia[J].Lancet,2018,392(10147):593-606.
